Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

<p>Raw data provided by Nanostring bioinformatic team</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Yeh Wang (14964041) (author)
Kolejni autorzy:	Peng Huang (14964044) (author), Brant G. Wang (14964047) (author), Tricia Murdock (14964050) (author), Leslie Cope (14964053) (author), Fang-Chi Hsu (14964056) (author), Tian-Li Wang (14964059) (author), Ie-Ming Shih (14964062) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Risk Factors Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Cancer Prevention Biomarkers Early detection biomarkers Cancer Interception Biomarkers and intervention Carcinogenesis Tumor initiation and promotion Epigenetics DNA methylation Gynecological Cancers Ovarian cancer Tumor Evolution
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
od: Yeh Wang (14964041)
Wydane: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
od: Christopher J. Gibson (15907642)
Wydane: (2025)

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
od: Christopher J. Gibson (15907642)
Wydane: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
od: Katleen Janssens (15053356)
Wydane: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
od: Félix Blanc-Durand (15049400)
Wydane: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
od: Jun Wang (15051911)
Wydane: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
od: Sanna Pikkusaari (15055802)
Wydane: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
od: Sanna Pikkusaari (15055802)
Wydane: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
od: Colin S. Wood (15293247)
Wydane: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Wydane: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
od: Athanasios Bikas (16006076)
Wydane: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
od: Daniel S. Green (15047598)
Wydane: (2025)

Supplementary file 3: Supplementary Tables. from circFNDC3B Accelerates Vasculature Formation and Metastasis in Oral Squamous Cell Carcinoma
od: Xiang Li (15386727)
Wydane: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
od: Laura Privitera (16015972)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5ujfc5ujkn4uffrmklra93s1dr